Publication | Closed Access

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentEgfr MutationsOncologyRadiation OncologyLung CancerMolecular Oncology